ABIONYX Pharma SA (EPA:ABNX)
France · Delayed Price · Currency is EUR 2.775
-0.025 (-0.89%)
Jun 3, 2026, 5:35 PM CET
ABIONYX Pharma Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4.06 | 4.55 | 4.64 | 5.25 | 0.68 | |
Revenue Growth (YoY) | -10.72% | -1.92% | -11.65% | 678.07% | - |
Cost of Revenue | 3.53 | 3.71 | 4.02 | 4.62 | 0.42 |
Gross Profit | 0.53 | 0.84 | 0.62 | 0.64 | 0.26 |
Selling, General & Admin | 4.57 | 3.43 | 2.61 | 3.66 | 2.34 |
Research & Development | 1.52 | 1.9 | 1.52 | 1.11 | 3.84 |
Other Operating Expenses | -0.02 | -0.02 | -0.1 | -0.02 | 0.04 |
Operating Expenses | 6.07 | 5.31 | 4.03 | 4.75 | 6.21 |
Operating Income | -5.54 | -4.47 | -3.41 | -4.11 | -5.95 |
Interest Expense | -0.09 | -0.04 | -0.02 | -0.06 | -0.01 |
Interest & Investment Income | 0.05 | 0.1 | 0.06 | 0.01 | 0 |
Currency Exchange Gain (Loss) | 0.04 | -0.03 | -0.04 | 0.04 | -0.02 |
Other Non Operating Income (Expenses) | -0.02 | 0.04 | -0.11 | -0.08 | 0.15 |
EBT Excluding Unusual Items | -5.54 | -4.38 | -3.52 | -4.21 | -5.82 |
Pretax Income | -5.54 | -4.38 | -3.52 | -4.21 | -5.82 |
Income Tax Expense | 0.01 | - | - | - | - |
Net Income | -5.55 | -4.38 | -3.52 | -4.21 | -5.82 |
Net Income to Common | -5.55 | -4.38 | -3.52 | -4.21 | -5.82 |
Shares Outstanding (Basic) | 35 | 34 | 29 | 28 | 25 |
Shares Outstanding (Diluted) | 35 | 34 | 29 | 28 | 25 |
Shares Change (YoY) | 3.73% | 14.80% | 4.95% | 12.41% | 5.92% |
EPS (Basic) | -0.16 | -0.13 | -0.12 | -0.15 | -0.23 |
EPS (Diluted) | -0.16 | -0.13 | -0.12 | -0.15 | -0.23 |
Free Cash Flow | -3.18 | -3.7 | -3.8 | -3.52 | -6.86 |
Free Cash Flow Per Share | -0.09 | -0.11 | -0.13 | -0.13 | -0.28 |
Gross Margin | 13.14% | 18.55% | 13.32% | 12.11% | 38.37% |
Operating Margin | -136.30% | -98.11% | -73.53% | -78.24% | -881.78% |
Profit Margin | -136.60% | -96.27% | -75.82% | -80.08% | -862.52% |
Free Cash Flow Margin | -78.14% | -81.34% | -81.94% | -67.10% | -1016.00% |
EBITDA | -5.42 | -4.34 | -3.27 | -3.99 | -5.83 |
EBITDA Margin | -133.47% | -95.36% | -70.50% | -75.91% | - |
D&A For EBITDA | 0.12 | 0.13 | 0.14 | 0.12 | 0.12 |
EBIT | -5.54 | -4.47 | -3.41 | -4.11 | -5.95 |
EBIT Margin | -136.30% | -98.11% | -73.53% | -78.24% | - |